Inovise Medical, Inc. to Present at Medtech Insight's ``Investment In Innovation'' Boston Conference.

BOSTON -- Inovise Medical, Inc.:

-- Inovise Medical, Inc. Has Announced That It Will Be Presenting at 11:00 am on Monday, October 10, 2005 at Medtech Insight's "Investment In Innovation (In3) BOSTON: A Preview of Early-Stage Medical Technology Companies" Conference, Taking Place October 10-11, 2005 at The Westin Copley Place Hotel in Boston, MA

Inovise Medical, Inc. is pioneering transformational medical technology that is shaping cardiac care worldwide. Inovise Medical's team of experts in the areas of diagnostic cardiology, patient monitoring, and biomedical engineering are developing innovative, non-invasive technologies for the fast, efficient, reliable, and cost-effective diagnosis and treatment monitoring of patients with high-risk cardiac conditions. Cardiovascular diseases, especially heart failure, are growing at epidemic rates in the United States. Currently, 4.9 million Americans have heart failure and 550,000 new cases are diagnosed each year.

The company's flagship technology, AUDICOR(R), first achieved recognition for both its innovation and value delivery as the winner of the Medical Design Excellence Award in 2004, the only awards program that exclusively recognizes contributions and advances in the design of medical products.

AUDICOR(R) is an easy-to-use, non-invasive diagnostic technology helping medical professionals quickly rule-in cardiac dysfunction including acute heart failure, acute coronary syndrome, and other high-risk cardiac conditions. Designed to seamlessly fit into the existing workflow, AUDICOR(R) products enable clinicians in the Emergency Room, as well as paramedics in the pre-hospital community, to rapidly and accurately assess patients presenting with shortness-of-breath. AUDICOR(R) diagnostic data helps contribute to earlier administration of definitive therapy, shorter length-of-stays, reduced hospitalizations, and reduced mortality.

AUDICOR(R) is the first technology to synchronize the electrical and mechanical activities of the heart to precisely detect, accurately interpret, and clearly document the presence of the third heart sound (S3) by using the company's patented Correlated Audioelectric Cardiography (COR) technology. Recently published research is emphasizing the diagnostic and prognostic role of the (S3) in diagnosing heart failure. Clinical studies demonstrate an S3 is present in greater than 50% of patients presenting with symptoms of decompensated heart failure, and in the presence of such symptoms, an S3 is a highly specific indicator of left ventricular dysfunction.

Auscultation of heart sounds is part of the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in Adults. However, in a noisy clinical environment, hearing the third heart sound (S3) by means of auscultation presents a significant challenge due to the S3's low frequency characteristics. Studies report physician auscultation detects only 1 out of 5 patients with heart failure. In contrast, AUDICOR(R) demonstrates 95% specificity, making it the most specific rule-in tool for heart failure.

Medtech Insight, a division of Windhover Information Inc., is the leading provider of business information and market intelligence for the medical technology marketplace. To register for the "Investment In Innovation Boston" conference or for more information on Medtech Insight, please call Kristy Grimes at [phone], e-mail [e-mail], or visit www.medtechinsight.com.